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deep vein thrombosis (DVT) can cause fatal pulmonary 
embolism (PE)
2) and prophylactic anticoagulants have been 
commonly used to prevent DVT. In this study, we assessed the 
efficacy of autologous transfusion of filtered shed blood on 




  Between January 2006 and May 2010, 42 female patients with 
unilateral TKA by a single surgeon were enrolled in the present 
study. Patients with a history of bleeding tendency were excluded. 
Fifteen TKA patients (group A) had a suction drain (Baro-Vac, 
Sewoon Medical, Cheonan, Korea) only without anticoagulant, 
while 27 TKA patients (group B) received autotransfusion 
(Consta-Vac, Stryker, Michigan, MI, USA) and anticoagulant 
therapy using Fondaparinux (Arixtra, Glaxo Smith Kline, 
London, England). The maximum negative pressure of Baro-Vac 
was 90 mm Hg and we used half pressure. The negative pressure 
of Consta-Vac was 50 mm Hg.
  The mean age of group A and B patients was 72.9 (range, 54 
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Purpose: To assess the efficacy and safety of autologous transfusion of filtered shed blood in total knee arthroplasty (TKA).
Materials and Methods: A total of 42 patients with TKA (group A; without autologous transfusion in 15 patients, group B; with autologous 
transfusion in 27 patients) were evaluated retrospectively. The influence of autologous reinfusion of filtered blood, bleeding tendency, amount of 
blood drainage, rate of allogenic transfusion, and the postoperative changes of hemoglobin were analyzed.
Results: Allogenic transfusion was needed in 26.7% (4/15) of group A and none of group B till postoperative 48 hours. Till postoperative 14 days, 
46.7% (7/15) of group A needed allogenic transfusion while 7.4% (2/27) in group B. The average drained blood volume was 1,197±400 mL in 
group A and 975±422 mL in group B. The average decrease of hemoglobin at postoperative 1, 7, and 14 days was 2.9±1.5, 2.9±1.6, and 2.3±1.5 g/dL 
respectively in group A and 2.7±0.8, 4.0±1.0, and 2.9±1.3 g/dL respectively in group B.
Conclusions: An autotransfusion system lowered the allogenic transfusion rate, while anticoagulants did not increase the amount of drained blood. 
An autotransfusion system with anticoagulants was effective and safe to save the shed blood in TKA.
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Introduction
  Suction drainage in total knee arthroplasty (TKA) has been used 
primarily to prevent hemoarthrosis, hematomas and infections, 
and secondly to promote wound healing and rehabilitation
1). In 
general, a large amount of blood is lost during and after surgery, 
which requires allogenic transfusion to stabilize the patient’s vital 
signs. To reduce the amount of allogenic transfusion, various 
autotransfusion systems have been introduced. TKA-associated 
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to 82) and 71.0 (range, 58 to 82) years, respectively. The average 
body mass index (BMI) was 26.5% (±3.2) in group A and 
24.6% (±3.0) in group B. The indication for TKA was primary 
osteoarthritis in all patients. The demographic data of the two 
groups were not significantly different (Table 1).
 
2. Operative Technique and Implants
  Regional anesthesia (spinal, epidural or spinal-epidural 
combined) was performed in all patients. In group A, 7 
spinal, 6 epidural and 2 spinal-epidural anesthesia types were 
used. In group B, 12 spinal, 10 epidural and 5 spinal-epidural 
anesthesia types were used. A unilateral, posterior substitute 
(PS) type cemented TKA using a medial parapatellar incision 
was performed. Patellar resurfacing was done and a pneumatic 
tourniquet was used during surgery in all patients. After 
tourniquet release, meticulous hemostasis was performed. The 
shed blood during this bleeding control period was discarded. 
Because the same operative procedure was performed in group 
A and B, we thought there were no significant differences in the 
discarded blood. Therefore, the blood lost during surgery was not 
measured and not included in this study. 
  In group A, 8 genesis II (Smith & Nephew, Memphis, TN, USA) 
and 7 Scorpio (Osteonics, NJ, USA) were used, and in group B, 
11 Genesis II and 16 Scorpio were used. 
3. Postoperative Management
  Drainage was discontinued at 48 hours postoperatively in 
both groups because of a potential increase in the bacterial 
colonization rate if left longer. Group B patients received 
autotransfusion of the drained filtered blood that was collected 
during the first 6 postoperative hours, and the subcutaneous 
anticoagulant (Fondaparinux 2.5 mg per day: Arixtra) therapy 
was started at 6 hours postoperatively until postoperative day 
7. In both groups, allogenic transfusion was indicated when the 
hemoglobin concentration was <7 g/dL or when vital signs were 
unstable or the hemoglobin concentration was <9 g/dL and acute 
hypovolemic symptoms developed such as hypotension below 
100 mm Hg of systolic blood pressure, tachycardia above 100/
min, decreased urine output below 20 mL/h, and dizziness
3,4). 
  To evaluate the clinical validity of autologous transfusion of 
the filtered shed blood, the frequency of allogenic transfusion 
was analyzed until the postoperative day 14, and the changes 
in hemoglobin were analyzed statistically at postoperative 24 
hours, day 7 and day 14. To evaluate the effect of anticoagulant 
prophylaxis on bleeding tendency, the amount of drained blood 
was analyzed till 48 hours postoperatively. The symptoms of 
thrombophlebitis were also checked till the 14th postoperative 
day. The percentage of patients needing an allogenic transfusion 
in each group was determined. Statistical analysis was performed 
using chi-square analysis for categorical data. The amount of 
drained blood and reduction in hemoglobin according to the 
usage of anticoagulants were compared statistically by conducting 
the Student’s t-test. All statistical analyses were performed with 
an IBM SPSS statics ver. 19 (IBM Corporation, Somers, NY, 
USA). A p-value<0.05 was considered statistically significant. 
Results
1. The Frequency of Allogenic Transfusion
  Allogenic transfusion was needed in 26.7% (4/15) of patients 
in group A and none in group B until 48 hours postoperatively. 
Until postoperative day 14, transfusion was needed in 46.7% 
(7/15) of patients in group A and 7.4% (2/27) in group B. 
Statistically, the autotransfusion system reduced allogenic 
transfusion rates (p<0.05) (Table 2).
 
2. Autologous Tranfusion and Autotransfusion System-
Related Complications
  The average amount of autotransfusion was 490 mL (±202). No 
complications (febrile reaction, bacterial infection, fat embolism, 
Table 1. Demographic Data of the Patients in This Study
Group A Group B
No. of patients 15 27
Mean age 72.9 (54-82) 71.0 (58-82)
Body mass index (%) 26.5±3.2 24.6±3.0
Table 2. The Rate of Allogenic Transfusion, Amount of Drained Blood 






Allogenic transfusion (till POD 
2nd day)
4/15 (26.7) 0/27 (0)  0
Allogenic transfusion (till POD 
14th day)
7/15 (46.7) 2/27 (7.4) 0.005
Amount of drain (till 
postoperative 48 hr)
1,197±400  975±422 0.104
Preoperative hemoglobin (g/dL)    12.0±1.1  12.4±0.9  0.219
Change of Hb (POD 1, g/dL)      2.9±1.5    2.7±0.8  0.564
Change of Hb (POD 7, g/dL)     2.9±1.6   4.0±1.0 0.021
Change of Hb (POD 14, g/dL)     2.3±1.5   2.9±1.3 0.221
Values are presented as number (%) or mean±standard deviation.
POD: postoperative day, Hb: hemoglobin.16    Park et al. Autologous Transfusion of Filtered Shed Blood
coagulopathy, itching and urticaria, etc.) related to autologous 
transfusion of the filtered shed blood were noted clinically.
 
3. The Amount of Drained Blood
 The average amount of drained blood was 1,197 mL (±400) 
in group A and 975 mL (±422) in group B until 48 hours 
postoperatively. The use of an anticoagulant (Fondaparinux: 
Arixtra) did not result in significant increases in the amount of 
drained blood (p>0.05) (Table 2). 
 
4. The Average Hemoglobin Level
  The average preoperative hemoglobin level was 12.0 (±1.1) 
in group A and 12.4 (±0.9) in group B. The postoperative 
hemoglobin level was measured at postoperative days 2, 7 and 
14. The average decrease in the hemoglobin level at 24 hours 
postoperatively and at postoperative days 7 and 14 was 2.9 g/
dL (±1.5), 2.9 g/dL (±1.6) and 2.3 g/dL (±1.5), respectively, 
in group A and 2.7 g/dL (±0.8), 4.0 g/dL (±1.0) and 2.9 g/
dL (±1.3), respectively, in group B. A statistically significant 
intergroup difference was found in the value obtained at 24 hours 
postoperatively (p<0.05), not at postoperative days 7 and 14 
(p>0.05) (Table 2).
5. Complications Related to Prophylactic Anticoagulant 
Therapy
  No specific complication was noted postoperatively in group 
A and B. To diagnosis DVT, we checked clinical symptoms such 
as pain, edema, tenderness, body temperature, heart rate and 
Homan’s sign, and related symptoms were not noted in both 
groups. Particularly in group B with anticoagulant therapy, no 
complications such as bleeding, hematoma or wound problems 
developed until postoperative day 14. We did not find any 
surgical site complications that correlated with BMI either. The 
anesthesiologist did not consider the regional anesthesia method 
using anticoagulants. The epidural catheters were removed by 48 
hours postoperatively in all patients and no complication such as 
epidural hematoma developed.
Discussion
1. The Effect and Safety of Autologous Transfusion of Filtered 
Shed Blood
  Blood loss after TKA has been known to be about 500-1,500 
mL. It has been known that the amount of blood loss affects 
the prognosis of TKA
5). Therefore, various autotransfusion 
systems have been used to reduce the side effects of allogenic 
transfusion and to save shed blood. In some studies, autologous 
transfusion of filtered shed blood resulted in complications such 
as febrile reaction, hypotension, bacterial infection, fat embolism, 
coagulopathy, itching and urticaria
6-8). However, these side effects 
have been rarely reported. In addition, the safety of filtered shed 
autotransfusion has been documented in various studies
9-14). In 
our study, no complications related to autologous transfusion 
were noted in the clinical assessment.
  Allogenic transfusion was needed in 26.7% (4/15) of patients 
in group A and none in group B until 48 hours postoperatively. 
Until postoperative day 14, the transfusion was needed in 46.7% 
(7/15) of patients in group A and 7.4% (2/27) in group B. The 
autotransfusion system (Consta-Vac) was effective in lowering 
the incidence of allogenic transfusion at a significant level 
(p<0.001).
2. The Effect and Safety of Anticoagulant
  The use of prophylactic anticoagulant is important because the 
incidence of DVT after TKA is higher than other surgeries and 
DVT can cause fatal PE. Stulberg et al.
15) reported about 84% 
deep-vein thrombosis following total knee replacement without 
anticoagulant prophylaxis. Cha et al.
16) reported that venous 
thromboembolism occurred in 40.4% of cases following total 
knee replacement without anticoagulant prophylaxis and that 
TKA was a risk factor for DVT and PE. Some studies reported 
that the incidence of DVT in Asians was low
17,18), but recent 
epidemiological studies disclosed that the incidence of DVT in 
Asians has been increasing
19,20). Brookenthal et al.
2) reported the 
overall incidence of fatal PE was 0.22% and Howie et al.
21) and 
SooHoo et al.
22) reported 0.15% and 0.41% of fatal PE within 90 
days after TKA. The use of prophylactic anticoagulant is very 
important because of the high mortality of symptomatic PE
23).
  To prevent DVT, standard pneumatic compression, inferior 
vena cava filter and pharmacologic prophylaxis can be used. 
The existing pharmacologic options are parenteral heparin, oral 
warfarin (inhibitor of vitamin K), low-molecular-weight heparin 
(Dalteparin, Enoxaparin, Lovenox), Fondaparinux (inhibitor 
of factor Xa) and inhibitor of platelet aggregation (Aspirin, 
Naproxen, NSAIDs). An oral form of heparin (Melagtran, 
Ximelagatran, Dabigatran, Rivaroxaban, Apixaban) as well as 
direct thrombin inhibitors of factors IIa, IXa and Xa are being 
developed
24-26). Fondaparinux sodium (Arixtra 2.5 mg/0.5 
mL) is the first synthetic inhibitor of factor Xa and has a single 
molecular target within the coagulation cascade. In the current 
series, it was administered subcutaneously from 6 hours after 
surgery until 5-9 days following surgery (2.5 mg once daily)
27).Knee Surg Relat Res, Vol. 24, No. 1, Mar. 2012    17
  The anticoagulant-related complications include bleeding, 
hematoma and wound problem
5,28). However, Turpie
27) present-
ed rare side effects of fondaparinux including bleeding until 
postoperative day 11. To evaluate the effect and safety of anti-
coagulants on bleeding tendency, blood analysis has to be done 
but unfortunately it is an expensive procedure. Bleeding is the 
most concerning side effect of anticoagulant therapy. Therefore, 
we simply evaluated the amount of drained blood. It is simple 
and economical, and has high clinical validity. We believe the 
amount of drained blood reflects bleeding tendency clinically. 
In most cases, bleeding stopped within 2-3 postoperative days, 
and consequently the drainage was also removed
1,6,9,10,29). The 
average amount of drained blood until 48 hours after surgery 
was 1,197 mL (±400) in group A and 975 mL (±422) in group B. 
Anticoagulant therapy did not significantly increase the amount 
of drained blood (p>0.05). High incidence of DVT can cause 
fatal PE secondarily. Therefore, a prophylactic anticoagulant is 
recommended. As a result, non DVT was complicated in the 
current series.
 
3. The Limitation of This Study
  Limitations of this study include the lack of providing the 
amount of blood loss during wound closure after tourniquet 
release, planned blood analysis (bleeding time, coagulation 
time and prothrombin time) and accurate diagnosis of DVT 
postoperatively. The assumptive asymptomatic complications 
such as hemoarthrosis and asymptomatic DVT have to be 
evaluated prospectively. 
  We expected that the average hemoglobin level would not be 
different between group A and B, but there were statistically 
significant differences at postoperative day 7. We hypothesized 
that this was attributable to either allogenic transfusion or the 
anticoagulant. In group A, allogenic transfusion was needed 
in 46.7% (7/15) of patients until postoperative day 7. In group 
B, allogenic transfusion was needed in 7.4% (2/27) of patients 
due to anemia at 7 days postoperatively and gastroduodenal 
ulcer at 10 days postoperatively. High frequency of allogenic 
transfusion in group A would have affected the hemoglobin 
level at 7 days postoperatively. Also, the hemodynamic effect of 
anticoagulants has the potential of lowering the hemoglobin at 
7 days postoperatively. Further evaluation is needed fully clarify 
this issue.
Conclusions
  An autotransfusion system (Consta-Vac) reduced the allogenic 
transfusion rates. Anticoagulants (Fondaparinux: Arixtra) did not 
increase the amount of drained blood. Autotransfusion system 
with anticoagulant was effective and safe to save shed blood and 
prevent thrombophlebitis and thromboembolism after TKA. 
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